Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual Meeting
  • June 7, 2021
  • Julie Ha

  EDISON, N.J., –(BUSINESS WIRE)– Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, announces the presentation of Phase 1 data for BDB001 in combination with pembrolizumab in advanced solid tumors at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. […]

Seven and Eight Biopharmaceuticals Inc. Announces Acceptance of BDB001 in Combination with Pembrolizumab Interim Data to be Presented in a Poster Discussion at the 2021 ASCO Annual Meeting
  • April 28, 2021
  • Julie Ha

  EDISON, N.J. –(BUSINESS WIRE)– Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.  The abstract detail […]

Seven and Eight Biopharma Presents Promising Interim Phase 1 Results for BDB001 at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
  • November 9, 2020
  • Melissa Harney

EDISON, N.J. – Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced interim Phase 1 results evaluating BDB001, its Toll-like receptor 7/8 (TLR7/8) agonist (NCT03486301), at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting to […]